These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21476920)

  • 21. Genetic influences in nonalcoholic fatty liver disease.
    Merriman RB; Aouizerat BE; Bass NM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S30-3. PubMed ID: 16540764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
    Anstee QM; Day CP
    Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function?
    Dubuquoy C; Burnol AF; Moldes M
    Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):30-5. PubMed ID: 22884299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
    Romeo S; Kozlitina J; Xing C; Pertsemlidis A; Cox D; Pennacchio LA; Boerwinkle E; Cohen JC; Hobbs HH
    Nat Genet; 2008 Dec; 40(12):1461-5. PubMed ID: 18820647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease.
    Vazquez-Chantada M; Gonzalez-Lahera A; Martinez-Arranz I; Garcia-Monzon C; Regueiro MM; Garcia-Rodriguez JL; Schlangen KA; Mendibil I; Rodriguez-Ezpeleta N; Lozano JJ; Banasik K; Justesen JM; Joergensen T; Witte DR; Lauritzen T; Hansen T; Pedersen O; Veyrie N; Clement K; Tordjman J; Tran A; Le Marchand-Brustel Y; Buque X; Aspichueta P; Echevarria-Uraga JJ; Martin-Duce A; Caballeria J; Gual P; Castro A; Mato JM; Martinez-Chantar ML; Aransay AM
    Hepatology; 2013 Feb; 57(2):505-14. PubMed ID: 22961556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methodological concerns about a recent meta-analysis of the influence of the I148M variant of patatin-like phospholipase domain containing 3 on the susceptibility and histological severity of nonalcoholic fatty liver disease.
    Liu L; Shao JH; Wang K; Hua FZ
    Hepatology; 2011 Jun; 53(6):2145; author reply 2146-7. PubMed ID: 21465506
    [No Abstract]   [Full Text] [Related]  

  • 27. Transcriptional networks in a rat model for nonalcoholic fatty liver disease: a microarray analysis.
    Sharma MR; Polavarapu R; Roseman D; Patel V; Eaton E; Kishor PB; Nanji AA
    Exp Mol Pathol; 2006 Dec; 81(3):202-10. PubMed ID: 16949573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic fatty liver disease in children.
    Mencin AA; Lavine JE
    Curr Opin Clin Nutr Metab Care; 2011 Mar; 14(2):151-7. PubMed ID: 21178608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon.
    Charlton M
    Am J Gastroenterol; 2007 Feb; 102(2):409-11. PubMed ID: 17311653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Family with sequence similarity 3 gene family and nonalcoholic fatty liver disease.
    Yang J; Guan Y
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():105-11. PubMed ID: 23855304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease.
    Miyaaki H; Nakao K
    Clin J Gastroenterol; 2017 Jun; 10(3):201-207. PubMed ID: 28290069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.
    Carter-Kent C; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Apr; 103(4):1036-42. PubMed ID: 18177455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic studies to identify hepatic fibrosis genes and SNPs in human populations.
    Day CP
    Methods Mol Med; 2005; 117():315-31. PubMed ID: 16118460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
    Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
    Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease?
    Canbakan B; Senturk H; Canbakan M; Toptas T; Tabak O; Balci H; Olgac V; Ozbay G
    Biomark Med; 2010 Apr; 4(2):205-14. PubMed ID: 20406065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic steatohepatitis and the metabolic syndrome.
    Jiang J; Torok N
    Metab Syndr Relat Disord; 2008 Mar; 6(1):1-7. PubMed ID: 18370830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Association of hepatic lipase gene promoter polymorphism -514C/T with nonalcoholic fatty liver disease].
    Zhan Q; Li YY; Nie YQ; Zhou YJ; DU YL; Sha WH; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2008 May; 16(5):375-8. PubMed ID: 18510853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver fibrogenesis and genetic factors.
    Boursier J; Louvet A
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S3-9. PubMed ID: 21742298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.